Objectives: Using an analysis test that is cost-efficient, determining which antibiotic therapy is most effective among several antibiotics. And to deliver superior care at a lower cost, to evaluate the risk factor that causes UTIs the most frequently, to determine efficacy of antibiotics used in UTIs, and to know the prescribing patterns involved in UTI patients in tertiary care hospital. Materials and Methods: The study was conducted prospective observational study using medical records and direct medical cost of UTI patients. The records of 200 patients met the inclusion criteria. Data processing and decision-making were carried out using descriptive and inferential statistical analysis, Average Cost-Effectiveness (ACER) calculation, and a cost-effectiveness grid. The outcome parameter used in a cost-effectiveness analysis was the percentage of effectiveness of antibiotics. Results: With an ACER of 821, ofloxacin IV is clearly the most economical choice. Additionally, it has a 100% efficacy rate. Despite having a high efficacy rate of 97.36%, Meropenem IV has the highest ACER (7294), making it the least cost-effective of the mentioned options. The ACER values of Doxycycline IV and Niftas P/O are in the middle. Piptaz IV's ACER is modest, and its effectiveness rate is quite low at 69.23%. Conclusion: Using the cost-effectiveness grid, Ofloxacin is more effective therapy, therefore treatment of UTIs using Ofloxacin is more cost beneficial.
